TandemAI provides an AI and physics-based platform for integrated drug discovery.

TandemAI

TandemAI is an advanced technology company dedicated to reinventing drug discovery infrastructure. The company integrates proprietary AI-driven, high-performance computation with its efficient, large-scale in-house wet lab operations to deliver a turnkey drug discovery solution. TandemAI has built its networked platform from the ground up in the U.S. and China to increase the speed of drug discovery and deliver cost-effective opportunities to its partners and to the global scientific community.

OrbiMed

Chengwei Capital

Eight Roads Ventures

F-Prime Capital

Qiming Venture Partners

We are in Denver, at Fall ACS! Please join Chuan Tian as he presents this afternoon about the impact of physics-based potency prediction on drug discovery at 3:35 PM MDT in Hall D – Room 1.

 Please also visit Evgeny Gutkin’s poster on physics-based approaches for predicting critical PharmaKinetics properties of small molecules this evening from 7 PM – 9 PM MDT in Hall A-C, poster board #631
#drugdiscovery #FEP #ACSFALL2024

🌟 Exciting Recap! 🌟

Last week, TandemAI’s Chuan Tian delivered an insightful lecture at the inaugural Amber Free Energy Workshop at UCSD, focusing on improving the reliability of free energy calculations with enhanced sampling.

The workshop featured a series of lectures and hands-on exercises designed to equip computational scientists with the best practices for conducting accurate, efficient, and reliable free energy studies. We are proud to have Dr. Tian represent TandemAI and contribute to the advancement of computational science!

#FreeEnergy #MolecularDynamics #ComputationalChemistry #TandemAI #AmberWorkshop #UCSD

🌟 Join Us To Learn What's New In TandemViz!
We’re excited to announce a special webinar featuring the latest innovations in TandemViz.

📅 Save the Date: Tuesday, August 6th 2:00 PM (EST)
📍 Register Here On LinkedIn

During the event, we'll cover new features, including expanded FEP capabilities, enhanced collaboration tools, simplified computation reuse, and easy external data uploads. Plus, get a sneak peek at the next phase of TandemViz development.
 
🎤 Hosted by:
Frederick Parsons, Director, Head of Scientific Visualization
Abir Ganguly, Director, Head of Free Energy

They’ll guide you through the latest features, including how these innovations can transform your approach to drug discovery.

P.S. Can't attend live? Don't worry! On-demand access will be available to registered participants.

Metric
Company Name	TandemAI
Symbol
MSH ID	COM:TANDEMAI
Market	PRIVATE
Sector	Healthcare & Health Services
Industry	Biotechnology
Country	US
Stage
Employee Count	59
Website	tandemai.com
LinkedIn	tandemai
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

COM:TANDEMAI

TandemAI

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue